INTRODUCTION
============

The mixed features specifier introduced in the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), it has been changed more dimensionally (more than two or three \[hypo\]manic symptoms+ principle depressive symptoms) in major depressive episodes (MDEs) of mood disorders. As a result of this change, estimates of the prevalence of episodes with mixed features have varied widely because the definition of this specifier has differed across studies. The reported prevalence of MDEs with mixed features has ranged from 46.4% to 73.1% in bipolar disorder (BD) and from 7.6% to 48.7% in major depressive disorder (MDD).[@b1-cpn-16-376]--[@b6-cpn-16-376] Mixed features are associated with a more severe clinical course, including earlier onset, frequent recurrence, greater risk of comorbid disorders, longer time to remission, poorer response to pharmacological treatment, and higher suicide risk, compared with pure affective episodes.[@b7-cpn-16-376],[@b8-cpn-16-376] Thus, the treatment of MDEs with these clinical features is difficult and requires additional attention.

Despite the clinical severity of MDEs, few studies have investigated pharmacological treatments for this condition or performed only subgroup analyses or post hoc analyses in patients with manic episodes. However, most studies use narrow diagnostic criteria for mixed episodes that include the 4th edition of DSM (DSM-IV) text revision criteria for simultaneously meet full criteria for both MDEs and manic episode.[@b9-cpn-16-376] It is difficult to apply these criteria to MDEs with mixed features because it presents the major polarity for depression and additional (hypo)manic symptoms.

Therefore, we reviewed the evidence for the efficacy of pharmacological treatments according to dimensional criteria for MDEs with mixed features.

METHODS
=======

Literature Search
-----------------

We systematically reviewed published randomized controlled trials (RCTs) of pharmacological treatments for MDEs with mixed features occurring in the course of mood disorders, including MDD and BD. We searched the PubMed, Cochrane Library, and [ClinicalTrials.gov](http://ClinicalTrials.gov) databases through December 2017 with the following key word combinations linked with the word OR: (a) mixed, mixed state, mixed features, DMX, mixed depression; (b) depressive, major depressive, MDE, MDD, bipolar, bipolar depression; and (c) antidepressant, antipsychotic, mood stabilizer, anticonvulsant, treatment, medication, algorithm, guideline, pharmacological.

Study Selection
---------------

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PRISMA; [Fig. 1](#f1-cpn-16-376){ref-type="fig"}).[@b10-cpn-16-376] Studies that met the following criteria were included in the analysis: 1) published studies of MDEs with mixed features (MDD or BD) using dimensional criteria (more than two or three symptoms with the opposite polarity); 2) studies based on RCTs; and 3) original articles.

RESULTS
=======

Of the 36 studies assessed for eligibility, 11 (six related to MDD and five related to BD) were included in the analysis. The small number of studies eligible for our analysis demonstrates that pharmacological treatment for MDEs with mixed features that meet DSM-5 criteria is an understudied area.

Of the studies originally identified, 25 did not meet the inclusion criteria. In those, three was a just conference abstract and 15 were excluded because the aim or design was not appropriate. Furthermore, because our focus was on depression with mixed features, which is largely unstudied, seven studies with inappropriate subgroup allocations were excluded.

Major Depressive Disorder
-------------------------

The findings related to MDD are shown in [Table 1](#t1-cpn-16-376){ref-type="table"}.[@b11-cpn-16-376]--[@b16-cpn-16-376] The majority of studies of MDD with mixed features have focused on the antipsychotic drugs, lurasidone and ziprasidone. In particular, we found five *post-hoc* studies of lurasidone based on one backbone study. In the original study, patients were randomly assigned to 6 weeks of double-blind treatment with lurasidone (20--60 mg/day, n=109) or placebo (n=100).[@b11-cpn-16-376] Lurasidone significantly improved the severity of the depressive symptoms compared with their baseline levels according to the Montgomery--Åsberg Depression Rating Scale (MADRS;−20.5 vs. −13.0, respectively; effect size=0.80) and the Clinical Global Impression Scale (CGI; −1.5 vs. −1.2, respectively; effect size=0.60) scores. Moreover, the assessment of manic symptoms, a mixed feature associated with MDD, using the Young Mania Rating Scale (YMRS) revealed significant improvement after the 6-week course of lurasidone. The incidence of side effects was similar to that associated with the placebo (40.4% vs. 38.0%, respectively), with nausea and somnolence reported to be the major side effects.[@b11-cpn-16-376]

Two studies investigated the primary end points associated with anxiety and irritability, which are major symptoms of MDE with mixed features. Tsai *et al*.[@b12-cpn-16-376] assessed the effect of lurasidone on baseline anxiety. The Hamilton Anxiety Rating Scale (HAM-A) was used to identify patients with mild anxiety (HAM-A, ≤14) and moderate-to-severe anxiety (HAM-A, ≥15) at baseline. Lurasidone treatment was associated with significant improvement (vs. placebo) in patients with mild (−7.6 vs. −4.0, respectively; *p*\<0.01, effect size=0.62) and moderate-to-severe (−11.4 vs. −6.1, respectively; *p*\<0.0001, effect size=0.91) anxiety. Swann *et al*.[@b13-cpn-16-376] found that lurasidone significantly improved depressive symptoms in patients with and without irritability as measured by the irritability and disruptive aggression items on the YMRS. Moreover, compared with placebo, lurasidone significantly reduced irritability in those with MDE with mixed features with irritable features (irritability item: −1.4 vs. −0.3, respectively; *p*=0.0012, effect size=1.0; disruptive-aggressive item: −1.0 vs. −0.3, respectively; *p*=0.0002, effect size= 1.2).[@b13-cpn-16-376]

Menopause is an important clinical variable of MDEs with mixed features. In a *post-hoc* study, Sramek *et al*.[@b14-cpn-16-376] found that lurasidone was an effective treatment for patients with post-menopausal MDD with mixed features (*p*=0.0056, effect size=0.96).

A *post-hoc* analysis of a RCT with an open-label extension of lurasidone assessed remission and recovery in patients with MMD with mixed features using the MADRS and Sheehan Disability Scale scores.[@b15-cpn-16-376] Compared with those who received placebo, a significantly higher proportion of patients treated with lurasidone achieved recovery at week 6 (assessed crosssectionally), and this was sustained at 1 and 3 months. Furthermore, the sustained recovery rate was higher in the lurasidone-to-lurasidone (20.8%) than the placebo-to-lurasidone (12.5%) arm of the extension study.

In a double-blind, prospective, 13-week crossover trial, patients with bipolar spectrum disorder were randomly assigned to a ziprasidone-washout-placebo or a placebo-washout-ziprasidone group. The authors found that ziprasidone (MADRS score change of −1.57±1.67; *p*=0.48) was not more effective than placebo.[@b16-cpn-16-376] Although this study may be controversial in terms of its use of bipolar spectrum disorder, the criteria for distinguishing bipolarity in MDD reflect most of the characteristics of MDD with mixed features. Moreover, the view that the mixed features specifier for MDD represents a structural bridge between MDD and BD recognizes that bipolar spectrum disorder is similar to MDD with mixed features.[@b17-cpn-16-376]

Bipolar Disorder
----------------

The principle pharmacological treatments for MDEs with mixed features associated with BD are olanzapine/olanzapine+fluoxetine (OFC), lurasidone, and ziprasidone ([Table 2](#t2-cpn-16-376){ref-type="table"}).

In a post-hoc study based on an 8-week trial, Benazzi *et al*.[@b18-cpn-16-376] compared the responses to olanzapine (5--20 mg/d; n=351), OFC (6/25, 6/50, 12/50 mg/d; n=82), and placebo (n=355) in patients with BD I depression with two or more manic symptoms. A therapeutic response was defined as a ≥50% reduction in the MADRS score and \<2 concurrent hypo/manic symptoms. The authors concluded that OFC may be an effective treatment for BD I depression with mixed features, although the difference in efficacy between OFC and olanzapine monotherapy was not statistically significant (OFC vs. olanzapine: odds ratio \[OR\]=2.00, 95% confidence interval \[CI\], 0.96--4.19; OFC vs. placebo: OR=3.91, 95% CI, 1.80--8.49; olanzapine vs. placebo: OR=1.95, 95% CI, 1.14--3.34).[@b18-cpn-16-376]

A recent study measured changes in the MADRS score from baseline to 6 weeks to compare the effects of olanzapine (n=690) and placebo (n=524) on the number of concurrent manic symptoms in patients with BD I depression with mixed features.[@b19-cpn-16-376] The change in the MADRS score was significantly greater in the olanzapine than in the placebo group, irrespective of the number of manic symptoms (−3.76, *p*=0.002; −3.20, *p*\<0.001; and −3.44, *p*=0.002 for 0, 1 or 2, and ≥3 mixed features, respectively).[@b19-cpn-16-376]

Similar to those examining MDD with mixed features, several RCTs have assessed the efficacy of lurasidone for the treatment of BD I depression with mixed features. One study found that mixed features were present in 56% of the patients with BD I at baseline, and treatment with lurasidone (vs. placebo) significantly reduced MADRS scores in this group (−15.7 vs. −10.9, respectively; *p*=0.001; week 6; mixed model for repeated measures; effect size=0.48).[@b20-cpn-16-376] Moreover, in terms of safety and tolerability, the incidence of adverse events associated with lurasidone that were reported by at least 5% of the participants was higher in the group with mixed features than in those without mixed features (nausea: 16.1% vs. 11.0%, respectively; and akathisia: 12.4% vs. 5.5%, respectively). However, the risk of treatment-emergent hypomania or mania was not increased.[@b20-cpn-16-376]

An investigation of the efficacy of ziprasidone in patients with MDEs with mixed features associated with BD II and MDD found that the change in the MARDS change from baseline was greater in the ziprasidone than in the placebo group (*p*=0.0038) and that the effect was more pronounced in the BD II compared to the MDD group.[@b21-cpn-16-376] In terms of safety and tolerability, no significant changes were observed in weight, akathisia, extrapyramidal symptoms, or incidence of headache/drowsiness. A subsequent study conducted to identify predictors associated with the response to ziprasidone or remission in patients with mixed depressive states found no predictor variables.[@b22-cpn-16-376]

DISCUSSION
==========

We reviewed clinical studies of pharmacological treatments for MDEs with mixed features associated with MDD and BD diagnosed according to DSM-5 criteria. However, the criteria for the DSM-5 mixed-features specifier differ from those for the DSM-IV mixed-episode criteria, and most studies of mixed features have focused on mania (mixed mania) rather than on depression (depressive mixed state). As a result, our analysis included only 11 studies.

Atypical antipsychotics are the mainstay of the pharmacological treatment for MDEs with mixed features. Our findings are consistent with those of a previous study that found that atypical antipsychotics were a more effective treatment for depressive symptoms with mixed episodes than was placebo, although their diagnoses were based on the DSM-IV text revision criteria for "mixed episodes (co-occurrence of full mania and full MDEs)."[@b23-cpn-16-376] Among lurasidone related to studies, Nelson *et al*.[@b24-cpn-16-376] reported that lurasidone improved depression regardless of baseline depression severity. Additionally, Pikalov *et al*.[@b25-cpn-16-376] found that it significantly improved manic and depressive symptoms and that the efficacy of the drug was moderated by the characteristics of the manic symptoms. However, because these findings were unpublished poster abstracts, they were not included in our study. The findings of numerous studies on the efficacy of antipsychotics for the treatment of mood disorders support guidelines recommending the use of atypical antipsychotic monotherapy (lurasidone, asenapine, quetiapine, quetiapine extended release, aripiprazole, and ziprasidone) as the first line of treatment for mixed depression.[@b26-cpn-16-376]

Large clinical studies of antidepressants and mood stabilizers or of combination therapies are lacking. Based on the findings of observational studies, antidepressants appear to be less effective for mixed states than for pure depression (MDEs with no manic symptoms).[@b27-cpn-16-376] Expert consensus guidelines warn that the monotherapy of anti-depressants for MDEs with mixed features may exacerbate subthreshold manic symptoms that accompany depression.[@b26-cpn-16-376],[@b28-cpn-16-376],[@b29-cpn-16-376] However, the most recent pharmacological treatment guideline for mixed features associated with MDD recommend 4- to 8-week trial of an adequate dose of antidepressant monotherapy and assessed subsyndromal hypomania related to the therapeutic outcomes as the initial treatment.[@b30-cpn-16-376] Given the paucity of systematic studies of antidepressants in patients with mixed features associated with MDD according to DSM-5 criteria, considering the clinical situation and the risk/benefit ratio, there was not sufficient evidence to prevent the use of antidepressants.

Treatment guidelines also recommend monotherapy with mood stabilizers, including lithium, lamotrigine, and valproate, or mood stabilizers in combination with antipsychotics as the first or second lines of treatment. These recommendations are supported by a previous study that found that divalproex with adjunctive olanzapine produced a greater and earlier reduction in manic and depressive symptoms in mixed-episode patients compared to placebo.[@b31-cpn-16-376] Mood stabilizers are widely used in the acute and maintenance phases of treatment despite insufficient evidence for their clinical use in patients with BD with depression with or without mixed features. Furthermore, the use of mood stabilizers has been shown to be a practical treatment strategy for MDD because the mixed-features specifier is associated with a decreased response to conventional antidepressant treatment and with a possible bipolar spectrum disorder.

Interestingly, improvement of (hypo)manic symptoms rather than of the main symptoms of depression may contribute to the enhancement of the response to treatment. Goldberg *et al*.[@b15-cpn-16-376] found that the number of manic symptoms among those with MDD at baseline was a significant moderator of cross-sectional recovery at week 6 (two manic symptoms: 36.4% vs. 8.2%, number needed to treat \[NNT\]=4; three manic symptoms: 22.5% vs. 18.9%, NNT=28). Moreover, an investigation of OFC efficacy, found that a higher number of concurrent (hypo)manic symptoms at baseline predicted a lower response rate in the olanzapine and placebo arms, but not in the OFC arm of the study.[@b18-cpn-16-376] This may mean that the poor response to conventional pharmacological treatment, which depends on the severity of mixed features. Controlled trials are needed to further investigate monotherapies and combination therapies with the various antipsychotics and mood stabilizers associated with improved manic symptoms.

Our study has several limitations. First, we may have omitted a number of relevant studies (observational studies, unpublished studies, reviews, or case reports) because only published original articles were included in this study. Second, given the relatively small number of evidence-based studies available, we lacked the power to offer clear clinical recommendations.

In conclusion, few studies have investigated pharmacological treatments for patients with MDEs with mixed features, and treatment guidelines also contain on a number of empirical grounds. Most of the studies we identified focused on antipsychotic drugs, whereas controlled trials of antidepressants and mood stabilizers were lacking. Antipsychotics, such as lurasidone, ziprasidone, and olanzapine/OFC, were effective for patients with MDEs with mixed features. Although, the use of antidepressants alone is controversial according to the guidelines, it is necessary to screen for clinical characteristics, such as bipolarity, and assess exacerbation of the (hypo)manic symptoms associated with MDD. Moreover, improvement of the (hypo)manic symptoms associated with MDEs with mixed features may be a more important parameter for prognosis and treatment than the dichotomy between MDD and BD. Further research on pharmacological treatments for MDEs with mixed features is needed.
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###### 

Randomized controlled trials in major depressive episode (MDE) with mixed features in major depressive disorders

  Study                                                        Duration (wk)   Medication                                              Primary measure                  Definition                          Results                                                Remark
  ------------------------------------------------------------ --------------- ------------------------------------------------------- -------------------------------- ----------------------------------- ------------------------------------------------------ -------------------------------------------------------------------------
  Suppes *et al.*[@b11-cpn-16-376] (2016)                      6               Lurasidone (20--60 mg/day, n=109) vs. placebo (n=100)   Changes from baseline in MADRS   MDE with 2--3 manic symptoms        −20.5 vs. −13.0 (effect size=0.80)                     m/c adverse events: nausea (6.4 % vs. 2.0%), somnolence (5.5% vs. 1.0%)
  *Post-hoc* studies                                                                                                                                                                                                                                               
   Tsai *et al*.[@b12-cpn-16-376] (anxiety)                                                                                                                                                                                                                        
   Swann *et al*.[@b13-cpn-16-376] (irritability)                                                                                                                                                                                                                  
   Sramek *et al*.[@b14-cpn-16-376] (post-menopause)                                                                                                                                                                                                               
   Goldberg *et al*.[@b15-cpn-16-376] (3 mo extension study)                                                                                                                                                                                                       
  Patkar *et al*.[@b16-cpn-16-376] (2015)                      13              Ziprasidone (20 mg bid--160 mg/d) vs. placebo (n=49)    Changes from baseline in MADRS   MDE with at least 3 of bipolarity   Nonsignificant (−1.57±1.67 in ziprasidone, *p*=0.48)   Crossover study

MADRS, Montgomery--Åsberg Depression Rating Scale; m/c, most common; bid, twice a day.

###### 

Randomized controlled trials in major depressive episode with mixed features in bipolar disorders

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                       Duration (wk)   Medication                                                                                      Primary measure                                                              Definition                                           Results                                                                                                                                                 Remark
  ------------------------------------------- --------------- ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  Tohen *et al*.[@b19-cpn-16-376] (2014)      6               Olanzapine (n=690) vs. placebo (n=524)                                                          Changes from baseline in MADRS                                               BD I depression with 0, 1 or 2, ≥3 manic symptoms    −3.76 (*p*=0.002) vs. −3.20 (*p*\<0.001) vs. −3.44 (*p*=0.002) for 0, 1 or 2, ≥3 manic symptoms                                                         *Post-hoc* analysis

  McIntyre *et al*.[@b20-cpn-16-376] (2015)   6               Lurasidone 20--120 mg (n=182) vs. placebo (n=90)                                                Changes from baseline in MADRS                                               BD I depression (MADRS ≥20, YMRS ≤12) with YMRS ≥4   −15.7 vs. −10.9 (*p*=0.001)                                                                                                                             *Post-hoc* analysis

  Patkar *et al*.[@b21-cpn-16-376]\           6               Ziprasidone (40--160 mg/day) vs. placebo (n=72)                                                 Changes from baseline in MADRS                                               BD II or MDD with 2 or 3 manic criteria              Ziprasidone \> placebo (*p*=0.0038), BD II \> MDD (*p*=0.036)                                                                                           
  Pae *et al*.[@b22-cpn-16-376] (2012)                                                                                                                                                                                                                                                                                                                                                                                                                  

  Benazzi *et al*.[@b18-cpn-16-376] (2009)    8               Olanzapine (5--20 mg/day, n=351) vs. OFC (6/25, 6/50, 12/50 mg/day, n=82) vs. placebo (n=355)   Response (≥50% reduction) in MADRS and \<2 concurrent (hypo)manic symptoms   BD I depression with ≥2 manic symptoms               OFC vs. olanzapine: OR=2.00 (95% CI, 0.96--4.19); OFC vs. placebo: OR=3.91 (95% CI, 1.80--8.49); olanzapine vs. placebo: OR=1.95 (95% CI, 1.14--3.34)   *Post-hoc* analysis
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MADRS, Montgomery--Åsberg Depression Rating Scale; BD, bipolar disorder; YMRS, Young Mania Rating Scale; MDD, major depressive disorder; OFC, olanzapine+fluoxetine; OR, odds ratio; 95% CI, 95% confidence interval.
